Janone (ALTS) Competitors $5.56 -0.39 (-6.55%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ALTS vs. ALLO, CKPT, OLMA, CMPS, TKNO, ARCT, HRTX, BNTC, TRDA, and ATYRShould you be buying Janone stock or one of its competitors? The main competitors of Janone include Allogene Therapeutics (ALLO), Checkpoint Therapeutics (CKPT), Olema Pharmaceuticals (OLMA), COMPASS Pathways (CMPS), Alpha Teknova (TKNO), Arcturus Therapeutics (ARCT), Heron Therapeutics (HRTX), Benitec Biopharma (BNTC), Entrada Therapeutics (TRDA), and Atyr PHARMA (ATYR). These companies are all part of the "pharmaceutical products" industry. Janone vs. Allogene Therapeutics Checkpoint Therapeutics Olema Pharmaceuticals COMPASS Pathways Alpha Teknova Arcturus Therapeutics Heron Therapeutics Benitec Biopharma Entrada Therapeutics Atyr PHARMA Allogene Therapeutics (NASDAQ:ALLO) and Janone (NASDAQ:ALTS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, community ranking, profitability, dividends, earnings and media sentiment. Which has better valuation & earnings, ALLO or ALTS? Janone has higher revenue and earnings than Allogene Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllogene Therapeutics$22K16,591.15-$327.27M-$1.33-1.26Janone$12.53M7.13-$7.81MN/AN/A Do analysts rate ALLO or ALTS? Allogene Therapeutics currently has a consensus target price of $9.29, suggesting a potential upside of 452.91%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than Janone.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allogene Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Janone 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ALLO or ALTS more profitable? Allogene Therapeutics' return on equity of -52.13% beat Janone's return on equity.Company Net Margins Return on Equity Return on Assets Allogene TherapeuticsN/A -52.13% -41.29% Janone N/A -2,940.01%-39.81% Which has more risk & volatility, ALLO or ALTS? Allogene Therapeutics has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Comparatively, Janone has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500. Do insiders & institutionals have more ownership in ALLO or ALTS? 83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 6.3% of Janone shares are held by institutional investors. 24.3% of Allogene Therapeutics shares are held by insiders. Comparatively, 4.9% of Janone shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community prefer ALLO or ALTS? Allogene Therapeutics received 284 more outperform votes than Janone when rated by MarketBeat users. CompanyUnderperformOutperformAllogene TherapeuticsOutperform Votes28465.89% Underperform Votes14734.11% JanoneN/AN/A Does the media prefer ALLO or ALTS? In the previous week, Allogene Therapeutics had 4 more articles in the media than Janone. MarketBeat recorded 5 mentions for Allogene Therapeutics and 1 mentions for Janone. Janone's average media sentiment score of 1.89 beat Allogene Therapeutics' score of 0.81 indicating that Janone is being referred to more favorably in the news media. Company Overall Sentiment Allogene Therapeutics Positive Janone Very Positive SummaryAllogene Therapeutics beats Janone on 9 of the 14 factors compared between the two stocks. Get Janone News Delivered to You Automatically Sign up to receive the latest news and ratings for ALTS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALTS vs. The Competition Export to ExcelMetricJanonePharmaceutical IndustryFinance SectorNASDAQ ExchangeMarket Cap$89.40M$6.89B$11.12B$7.83BDividend YieldN/A3.05%5.79%4.22%P/E RatioN/A7.4422.0018.48Price / Sales7.13242.7026.07103.59Price / CashN/A65.8517.6034.62Price / Book-8.306.512.654.25Net Income-$7.81M$143.21M$1.03B$248.23M7 Day Performance-3.97%1.98%0.57%0.89%1 Month Performance24.94%6.89%-0.43%3.53%1 Year PerformanceN/A-2.52%537.91%5.08% Janone Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTSJanoneN/A$5.56-6.6%N/AN/A$89.40M$12.53M0.00170News CoveragePositive NewsALLOAllogene Therapeutics3.2171 of 5 stars$1.57+10.2%$9.29+493.5%-39.1%$340.02M$22,000.00-1.00310Gap DownCKPTCheckpoint Therapeutics2.4031 of 5 stars$4.04-0.1%$4.33+7.4%+195.7%$337.99M$41,000.00-2.1910OLMAOlema Pharmaceuticals2.4922 of 5 stars$4.94+3.9%$27.67+460.6%-49.3%$337.22MN/A-2.2570Upcoming EarningsAnalyst ForecastPositive NewsCMPSCOMPASS Pathways2.4066 of 5 stars$3.58+5.8%$20.20+465.0%-53.6%$330.84MN/A-1.62120Upcoming EarningsNews CoveragePositive NewsHigh Trading VolumeTKNOAlpha Teknova1.9104 of 5 stars$6.15+6.5%$8.50+38.1%+274.7%$330.24M$37.75M-8.35240News CoverageARCTArcturus Therapeutics2.9602 of 5 stars$12.13+10.2%$59.20+388.2%-49.9%$330.08M$138.39M-5.48180News CoveragePositive NewsGap DownHRTXHeron Therapeutics3.7183 of 5 stars$2.17+12.2%$5.67+161.7%+4.3%$329.79M$144.29M-12.03300Upcoming EarningsNews CoveragePositive NewsGap UpBNTCBenitec Biopharma2.6758 of 5 stars$13.94+1.0%$24.71+77.4%+60.8%$327.85M$80,000.00-9.2620Positive NewsTRDAEntrada Therapeutics2.8762 of 5 stars$8.63+8.5%$25.67+197.6%-23.0%$322.00M$210.78M5.39110Upcoming EarningsNews CoverageATYRAtyr PHARMA2.3999 of 5 stars$3.48+5.9%$18.60+435.3%N/A$307.01M$235,000.00-3.6853Short Interest ↑News Coverage Related Companies and Tools Related Companies ALLO Alternatives CKPT Alternatives OLMA Alternatives CMPS Alternatives TKNO Alternatives ARCT Alternatives HRTX Alternatives BNTC Alternatives TRDA Alternatives ATYR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALTS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janone Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janone With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALTS Stock Free ALTS Stock Alerts